Aardvark Therapeutics Inc. (AARD)
NASDAQ: AARDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AARD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $20.20M
- EPS (TTM)
- -$3.33
- Dividend yield
- None
- 52-week range
- 0.90 – 16.60
- Day range
- 0.90 – 1.06
- Volume / Avg
- 241.07K / 643.53K
- Beta
- —
- Shares outstanding
- 21.89M
52-week range
AARD stock today
Aardvark Therapeutics (AARD) closed at $0.9226 on Nov 20, down 7.74% (-$0.0774), versus the S&P 500's 3.70% decline. Trading was light, with 241.07K shares changing hands, about 37% of the average daily volume. At this level, AARD sits near the bottom of its 52-week range of $0.90 to $16.60: 94.4% below the high, set on Jan 22, 2026 and 2.5% above the low.
AARD is down 93.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 90.2%. Aardvark Therapeutics has posted a net loss over the last twelve months (EPS of -$3.33), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aardvark Therapeutics
Company profileAardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Tien-Li Lee M.D.
- Headquarters
- San Diego, CA
- Employees
- 28
- IPO year
- 2025
- Website
- aardvarktherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Aardvark Therapeutics generated $0 in revenue. Aardvark Therapeutics reported a net loss of $57.6 million, compared with a loss of $20.6 million a year earlier. Diluted earnings per share came in at -$2.93.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $0 | — |
| Growth | — | — |
| Net income | $-57.59M | $-20.59M |
| EPS (diluted) | $-2.93 | $-5.15 |
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$11.11+1104.21%
- Strong buy 0
- Buy 6
- Hold 4
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.75 vs $-0.69
- Surprise
- -8.70%
AARD news
All AARD news- Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Agilent Technologies' Q4 Earnings on Deck: What's in Store for the Stock?NasdaqA, TGTX, CRBU, AARD
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike DealsNasdaqAARD, ABBV, ARTV, AZN
- Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension TrialsGlobeNewswire
- FDA Lifts Clinical Hold On Aardvark's ARD-101 For Prader-Willi Syndrome; Stock Up 16%NasdaqAARD, WSO.B
- Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE DataGlobeNewswire
- AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud LawsuitPR Newswire
- AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitPR Newswire
Aardvark Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNAZTransCode Therapeutics Inc. | 1.16 | -10.77% | $20.07M | vs AARD |
| ACETAdicet Bio Inc. | 2.14 | -13.01% | $20.03M | vs AARD |
| TXMDTherapeuticsMD Inc. | 1.71 | -5.52% | $19.79M | vs AARD |
| IGCIGC Pharma Inc. | 0.168 | -8.70% | $19.60M | vs AARD |
| CPHIChina Pharma Holdings Inc. | 0.4384 | -13.00% | $18.86M | vs AARD |
| CRVOCervoMed Inc. | 1.46 | +9.77% | $22.09M | vs AARD |
| COCPCocrystal Pharma Inc. | 0.95 | -2.05% | $18.30M | vs AARD |
| MRKRMarker Therapeutics Inc. | 1.09 | -17.42% | $18.17M | vs AARD |
Indexes, lists and sector
Aardvark Therapeutics stock FAQ
What is Aardvark Therapeutics's stock price today?
AARD last traded at $0.9226 as of Nov 20, 4:00 PM EST, down 7.74% on the day. Prices are delayed at least 15 minutes.
Who is Aardvark Therapeutics's CEO?
Dr. Tien-Li Lee M.D. is the chief executive officer of Aardvark Therapeutics Inc., which has about 28 employees.
What is the AARD 52-week high?
The 52-week high for AARD is $16.60 and the 52-week low is $0.90. The stock is currently 94.4% below its high.